Ashio

Ashio is a Seattle-based biotechnology company specializing in the development of circular RNA (circRNA) therapeutics. Leveraging foundational research from the University of Washington and the Brotman Baty Institute, the company aims to create a new class of stable, long-lasting RNA medicines. Ashio's platform focuses on optimizing circRNA for high-level protein expression and improved durability compared to traditional linear mRNA. The company is currently in the pre-clinical stage, building a pipeline of candidates to address a variety of therapeutic areas, including protein replacement and genetic diseases. Ashio is led by experienced executives from the biotech industry and backed by prominent venture capital firms.